Skip to main content
. 2016 Jul 22;8(33):54082–54095. doi: 10.18632/oncotarget.10789

Figure 7. Effect of JAK2 and PI3K inhibition on chemotaxis of MF CD34+ cells in response to CXCL12.

Figure 7

A. Jak2 protein level as revealed by Western-blot in HEL cells that express JAK2V617F. HEL cells were either non-infected (NI) or infected with control scramble (SCR) or V617F shRNA. A 95% reduction of the JAK2 protein was obtained with the V617F shRNA. B. JAK2 protein level was analyzed by Western-blot in MO7e cells that express the wild type form of JAK2. MO7e cells were either non-transduced (NI) or transduced with control scramble (SCR) or V617F shRNA. Results show a selective and specific inhibition of JAK2V617F protein expression present in HEL with shV617F, but not of the wild type form of JAK2 present in MO7e. C. Chemotactic responses to CXCL12 (100 ng/mL) of MF CD34+ cells expressing control scramble (SCR) or V617F shRNA. D. Effects of Ruxolitinib and BEZ235 inhibitors on MF CD34+ cell migration in response to CXCL12. Data are represented as mean ± SEM.